Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

This study has been completed.
Information provided by (Responsible Party):
Endo Pharmaceuticals Identifier:
First received: January 7, 2013
Last updated: October 30, 2014
Last verified: October 2014
This is an study evaluating the safety, tolerability, and PK of EN3342 in implantation durations of 6 months.

Condition Intervention Phase
Drug: EN3342
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH) Risperidone When Risperidone is Administered From a Polyurethane Implant

Resource links provided by NLM:

Further study details as provided by Endo Pharmaceuticals:

Primary Outcome Measures:
  • PK parameters (Cmax and AUC) for active moiety, 9-OH-risperidone and risperidone [ Time Frame: 6 months ]

Enrollment: 35
Study Start Date: October 2012
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EN3342
EN3342 (risperidone) subcutaneous implant
Drug: EN3342


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Subject Inclusion Criteria

  1. Subject (and/or a subject's authorized legal representative) has provided written informed consent
  2. Subject has identified a caregiver or personal contact with whom the subject has significant contact with at least once per week
  3. Subject is male or female of non-child bearing potential between 18 to 60 years of age inclusive
  4. Subject has a diagnosis of schizophrenia according to DSM-IV criteria
  5. Subject has a body mass index (BMI) ≥18.5 and ≤35.0 kg/m2
  6. Subject is assessed to be symptomatically stable by the Investigator, with regard to his or her psychiatric condition
  7. Subject is assessed by the Investigator to be symptomatically stable with regard to pre existing medical conditions as evidenced by medical history, clinically significant findings on physical examination, vital signs, clinical laboratory evaluations (hematology, serum chemistries, and urinalysis) or 12-lead electrocardiogram (ECG). Subjects may continue on their current medication regimen to control pre-existing medical and psychiatric (other than schizophrenia) conditions including the use of PRN medications.
  8. Subject is currently stable on a 4-, 6-, or 8-mg oral dose of risperidone for 30 days prior to admission

Subject Exclusion Criteria

  1. Known hypersensitivity or allergy to lidocaine or any local anesthetic agent of the amide type (local anesthetic used during implant and explant procedures)
  2. Known sensitivity to polyurethane
  3. Hospitalized or required acute crisis intervention for symptom exacerbation in the 30 days prior to admission as determined by the Investigator
  4. Subject has a history of suicide attempt in the last year, or in the opinion of the investigator is currently at imminent risk of suicide
  5. Reports or reveals a presence of clinically significant skin disorders (such as, but not limited to, skin cancer, psoriasis, eczema, or atopic dermatitis), evidence of recent sunburn, scar tissue, tattoo, open sore, body piercing or branding at the intended implantation site that would interfere with the implantation procedure or interfere with implant site assessments as determined by the Investigator
  6. History of abnormal scar formation or family history of keloid formation
  7. Have a positive screen for substances of abuse conducted at screening or had any history of abuse in the last six months as defined by DSM-IV criteria
  8. Have impaired hepatic (ALT/AST >1.5 times higher than the upper limit of normal) or renal function (eGFR <50mL/min)
  9. Previously defined hypersensitivity to risperidone
  10. History of neuromalignant syndrome (NMS)
  11. Electroconvulsive therapy within 6 months of admission
  12. Treatment of coexisting medical conditions that require the introduction of cytochrome P450 2D6 inhibitors or inducers
  13. Positive screen for Hepatitis B Surface Antigen (HBsAg), Hepatitis C Antibody (anti HCV), or human immunodeficiency virus (HIV) antibody and/or antigen
  14. Participation in the treatment phase of a clinical study or receipt of an investigational drug within 30 days prior to study drug administration on Day 1; for investigational drugs with an elimination half-life greater than 15 days, this time period will be extended to 60 days
  15. Prior participation in a EN3342 study
  16. Involvement in the planning and/or conduct of the study (applies to both Endo staff or staff at the investigational site)
  17. History of difficulty with phlebotomy procedures
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01774435

United States, New Jersey
CRI Lifetree
Marlton, New Jersey, United States
Sponsors and Collaborators
Endo Pharmaceuticals
Principal Investigator: Robert Litman, MD CBH Health LLC
  More Information

Responsible Party: Endo Pharmaceuticals Identifier: NCT01774435     History of Changes
Other Study ID Numbers: EN3342-102
Study First Received: January 7, 2013
Last Updated: October 30, 2014

Keywords provided by Endo Pharmaceuticals:
Stable Schizophrenic

Additional relevant MeSH terms:
Schizophrenia Spectrum and Other Psychotic Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents processed this record on April 25, 2017